Title: Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study Purpose: The goal of this clinical trial is to learn if single-session radiofrequency ablation (RFA) can effectively reduce the volume of benign thyroid nodules in adults. It will also evaluate the safety of the RFA procedure. The main questions it aims to answer are: 1. Does RFA procedure reduce the size of thyroid nodules (measured by volume reduction rate - VRR)? 2. What medical problems or complications do participants experience after undergoing RFA? 3. How does RFA affect thyroid hormone levels (TSH, FT4)? 4. Is RFA equally effective in purely cystic nodules, solid nodules, and predominantly cystic nodules? Comparator: This is a single-arm study, so there is no placebo or comparison treatment group. All participants will undergo RFA, and the results will be assessed over time. Participants will: * Undergo one session of RFA for benign thyroid nodules. * Be followed up with clinical visits and ultrasound assessments at 1, 6, and 12 months. * Have thyroid hormone levels tested and nodule size measured by ultrasound at each follow-up. * Be monitored for any side effects or complications such as voice changes, pain, or bleeding.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Volume Reduction Rate (VRR)
Timeframe: 1 month; 6 months; 12 months
volume reduction rate (VRR) at 1, 6, and 12 months post-procedure.
Timeframe: 1 month; 6 months; 12 months